nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2C9—brain cancer	0.462	1	CbGaD
Buprenorphine—CYP2D6—Lomustine—brain cancer	0.0464	0.14	CbGbCtD
Buprenorphine—CYP1A2—Carmustine—brain cancer	0.0459	0.138	CbGbCtD
Buprenorphine—ABCG2—Carboplatin—brain cancer	0.0393	0.118	CbGbCtD
Buprenorphine—CYP2D6—Hydroxyurea—brain cancer	0.0352	0.106	CbGbCtD
Buprenorphine—CYP3A4—Temozolomide—brain cancer	0.0347	0.104	CbGbCtD
Buprenorphine—ABCG2—Etoposide—brain cancer	0.033	0.0993	CbGbCtD
Buprenorphine—CYP3A4—Lomustine—brain cancer	0.0295	0.0887	CbGbCtD
Buprenorphine—CYP3A5—Etoposide—brain cancer	0.0183	0.055	CbGbCtD
Buprenorphine—CYP2C8—Etoposide—brain cancer	0.0176	0.0529	CbGbCtD
Buprenorphine—CYP1A2—Etoposide—brain cancer	0.0136	0.0409	CbGbCtD
Buprenorphine—ABCB1—Etoposide—brain cancer	0.0119	0.0358	CbGbCtD
Buprenorphine—CYP3A4—Etoposide—brain cancer	0.00713	0.0214	CbGbCtD
Buprenorphine—OPRM1—telencephalic ventricle—brain cancer	0.00246	0.0775	CbGeAlD
Buprenorphine—OPRD1—ganglion—brain cancer	0.00225	0.0707	CbGeAlD
Buprenorphine—OPRL1—brainstem—brain cancer	0.00189	0.0597	CbGeAlD
Buprenorphine—OPRL1—telencephalon—brain cancer	0.00168	0.053	CbGeAlD
Buprenorphine—OPRM1—ganglion—brain cancer	0.00153	0.0482	CbGeAlD
Buprenorphine—OPRL1—spinal cord—brain cancer	0.00118	0.0371	CbGeAlD
Buprenorphine—OPRL1—endocrine gland—brain cancer	0.00106	0.0334	CbGeAlD
Buprenorphine—OPRL1—head—brain cancer	0.00105	0.033	CbGeAlD
Buprenorphine—OPRL1—central nervous system—brain cancer	0.000956	0.0301	CbGeAlD
Buprenorphine—OPRD1—telencephalon—brain cancer	0.000866	0.0273	CbGeAlD
Buprenorphine—OPRL1—brain—brain cancer	0.000759	0.0239	CbGeAlD
Buprenorphine—UGT1A9—endocrine gland—brain cancer	0.000691	0.0218	CbGeAlD
Buprenorphine—OPRM1—brainstem—brain cancer	0.000666	0.021	CbGeAlD
Buprenorphine—CYP2C18—endocrine gland—brain cancer	0.000604	0.019	CbGeAlD
Buprenorphine—OPRM1—telencephalon—brain cancer	0.000591	0.0186	CbGeAlD
Buprenorphine—CYP3A7—endocrine gland—brain cancer	0.000575	0.0181	CbGeAlD
Buprenorphine—OPRD1—head—brain cancer	0.000539	0.017	CbGeAlD
Buprenorphine—OPRK1—head—brain cancer	0.000517	0.0163	CbGeAlD
Buprenorphine—OPRD1—central nervous system—brain cancer	0.000492	0.0155	CbGeAlD
Buprenorphine—OPRK1—central nervous system—brain cancer	0.000472	0.0149	CbGeAlD
Buprenorphine—CYP2D6—hindbrain—brain cancer	0.000466	0.0147	CbGeAlD
Buprenorphine—OPRK1—cerebellum—brain cancer	0.000461	0.0145	CbGeAlD
Buprenorphine—OPRM1—midbrain—brain cancer	0.000424	0.0134	CbGeAlD
Buprenorphine—OPRM1—spinal cord—brain cancer	0.000414	0.013	CbGeAlD
Buprenorphine—OPRD1—brain—brain cancer	0.000391	0.0123	CbGeAlD
Buprenorphine—OPRK1—brain—brain cancer	0.000375	0.0118	CbGeAlD
Buprenorphine—OPRM1—endocrine gland—brain cancer	0.000373	0.0117	CbGeAlD
Buprenorphine—OPRM1—head—brain cancer	0.000368	0.0116	CbGeAlD
Buprenorphine—CYP2A6—cerebellum—brain cancer	0.000352	0.0111	CbGeAlD
Buprenorphine—ABCB1—blood vessel—brain cancer	0.000351	0.0111	CbGeAlD
Buprenorphine—ABCG2—telencephalon—brain cancer	0.000345	0.0109	CbGeAlD
Buprenorphine—OPRM1—central nervous system—brain cancer	0.000336	0.0106	CbGeAlD
Buprenorphine—Upper respiratory tract infection—Temozolomide—brain cancer	0.00033	0.00288	CcSEcCtD
Buprenorphine—Shock—Procarbazine—brain cancer	0.000329	0.00286	CcSEcCtD
Buprenorphine—Depression—Carmustine—brain cancer	0.000327	0.00285	CcSEcCtD
Buprenorphine—Chills—Hydroxyurea—brain cancer	0.000327	0.00285	CcSEcCtD
Buprenorphine—Tachycardia—Procarbazine—brain cancer	0.000326	0.00284	CcSEcCtD
Buprenorphine—Hyperhidrosis—Procarbazine—brain cancer	0.000323	0.00281	CcSEcCtD
Buprenorphine—Weight decreased—Temozolomide—brain cancer	0.000321	0.0028	CcSEcCtD
Buprenorphine—Urinary tract infection—Carmustine—brain cancer	0.000319	0.00278	CcSEcCtD
Buprenorphine—Anorexia—Procarbazine—brain cancer	0.000319	0.00277	CcSEcCtD
Buprenorphine—Erythema—Hydroxyurea—brain cancer	0.000317	0.00276	CcSEcCtD
Buprenorphine—Infestation NOS—Temozolomide—brain cancer	0.000317	0.00276	CcSEcCtD
Buprenorphine—Infestation—Temozolomide—brain cancer	0.000317	0.00276	CcSEcCtD
Buprenorphine—Depression—Temozolomide—brain cancer	0.000316	0.00275	CcSEcCtD
Buprenorphine—Nausea—Lomustine—brain cancer	0.000313	0.00272	CcSEcCtD
Buprenorphine—Hypotension—Procarbazine—brain cancer	0.000312	0.00272	CcSEcCtD
Buprenorphine—Urinary tract infection—Temozolomide—brain cancer	0.000308	0.00268	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000304	0.00265	CcSEcCtD
Buprenorphine—Insomnia—Procarbazine—brain cancer	0.000302	0.00263	CcSEcCtD
Buprenorphine—Paraesthesia—Procarbazine—brain cancer	0.0003	0.00261	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Temozolomide—brain cancer	0.0003	0.00261	CcSEcCtD
Buprenorphine—Sinusitis—Temozolomide—brain cancer	0.000297	0.00259	CcSEcCtD
Buprenorphine—Somnolence—Procarbazine—brain cancer	0.000297	0.00259	CcSEcCtD
Buprenorphine—Cramp muscle—Etoposide—brain cancer	0.000296	0.00258	CcSEcCtD
Buprenorphine—Ill-defined disorder—Hydroxyurea—brain cancer	0.000294	0.00256	CcSEcCtD
Buprenorphine—Hallucination—Carmustine—brain cancer	0.000293	0.00255	CcSEcCtD
Buprenorphine—Hypoaesthesia—Carmustine—brain cancer	0.000293	0.00255	CcSEcCtD
Buprenorphine—Decreased appetite—Procarbazine—brain cancer	0.00029	0.00253	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Etoposide—brain cancer	0.00029	0.00253	CcSEcCtD
Buprenorphine—Oedema peripheral—Carmustine—brain cancer	0.00029	0.00253	CcSEcCtD
Buprenorphine—CYP2C8—pituitary gland—brain cancer	0.000289	0.00911	CbGeAlD
Buprenorphine—Connective tissue disorder—Carmustine—brain cancer	0.000289	0.00252	CcSEcCtD
Buprenorphine—Fatigue—Procarbazine—brain cancer	0.000288	0.00251	CcSEcCtD
Buprenorphine—Malaise—Hydroxyurea—brain cancer	0.000286	0.00249	CcSEcCtD
Buprenorphine—Constipation—Procarbazine—brain cancer	0.000286	0.00249	CcSEcCtD
Buprenorphine—Pain—Procarbazine—brain cancer	0.000286	0.00249	CcSEcCtD
Buprenorphine—CYP2A6—brain—brain cancer	0.000286	0.009	CbGeAlD
Buprenorphine—Dysphagia—Etoposide—brain cancer	0.000284	0.00248	CcSEcCtD
Buprenorphine—Visual impairment—Carmustine—brain cancer	0.000284	0.00247	CcSEcCtD
Buprenorphine—Hallucination—Temozolomide—brain cancer	0.000283	0.00246	CcSEcCtD
Buprenorphine—Hypoaesthesia—Temozolomide—brain cancer	0.000283	0.00246	CcSEcCtD
Buprenorphine—Pharyngitis—Temozolomide—brain cancer	0.000282	0.00246	CcSEcCtD
Buprenorphine—ABCG2—pituitary gland—brain cancer	0.000281	0.00886	CbGeAlD
Buprenorphine—Urinary tract disorder—Temozolomide—brain cancer	0.000281	0.00245	CcSEcCtD
Buprenorphine—Oedema peripheral—Temozolomide—brain cancer	0.00028	0.00244	CcSEcCtD
Buprenorphine—Bronchospasm—Etoposide—brain cancer	0.00028	0.00244	CcSEcCtD
Buprenorphine—Connective tissue disorder—Temozolomide—brain cancer	0.000279	0.00243	CcSEcCtD
Buprenorphine—Urethral disorder—Temozolomide—brain cancer	0.000279	0.00243	CcSEcCtD
Buprenorphine—Feeling abnormal—Procarbazine—brain cancer	0.000275	0.0024	CcSEcCtD
Buprenorphine—Eye disorder—Carmustine—brain cancer	0.000275	0.0024	CcSEcCtD
Buprenorphine—Convulsion—Hydroxyurea—brain cancer	0.000275	0.00239	CcSEcCtD
Buprenorphine—Visual impairment—Temozolomide—brain cancer	0.000274	0.00239	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Procarbazine—brain cancer	0.000273	0.00238	CcSEcCtD
Buprenorphine—Flushing—Carmustine—brain cancer	0.000273	0.00238	CcSEcCtD
Buprenorphine—ABCG2—medulla oblongata—brain cancer	0.000271	0.00855	CbGeAlD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000268	0.00233	CcSEcCtD
Buprenorphine—CYP2D6—brainstem—brain cancer	0.000267	0.00841	CbGeAlD
Buprenorphine—OPRM1—brain—brain cancer	0.000267	0.0084	CbGeAlD
Buprenorphine—Discomfort—Hydroxyurea—brain cancer	0.000267	0.00232	CcSEcCtD
Buprenorphine—Eye disorder—Temozolomide—brain cancer	0.000266	0.00232	CcSEcCtD
Buprenorphine—Urticaria—Procarbazine—brain cancer	0.000265	0.00231	CcSEcCtD
Buprenorphine—Tinnitus—Temozolomide—brain cancer	0.000265	0.00231	CcSEcCtD
Buprenorphine—Body temperature increased—Procarbazine—brain cancer	0.000264	0.0023	CcSEcCtD
Buprenorphine—Abdominal pain—Procarbazine—brain cancer	0.000264	0.0023	CcSEcCtD
Buprenorphine—Flushing—Temozolomide—brain cancer	0.000264	0.0023	CcSEcCtD
Buprenorphine—Cardiac disorder—Temozolomide—brain cancer	0.000264	0.0023	CcSEcCtD
Buprenorphine—Oedema—Hydroxyurea—brain cancer	0.000259	0.00225	CcSEcCtD
Buprenorphine—Angiopathy—Temozolomide—brain cancer	0.000258	0.00225	CcSEcCtD
Buprenorphine—Mental disorder—Carmustine—brain cancer	0.000258	0.00225	CcSEcCtD
Buprenorphine—Infection—Hydroxyurea—brain cancer	0.000257	0.00224	CcSEcCtD
Buprenorphine—Immune system disorder—Temozolomide—brain cancer	0.000257	0.00224	CcSEcCtD
Buprenorphine—CYP2C19—endocrine gland—brain cancer	0.000257	0.00809	CbGeAlD
Buprenorphine—Mediastinal disorder—Temozolomide—brain cancer	0.000256	0.00223	CcSEcCtD
Buprenorphine—Erythema—Carmustine—brain cancer	0.000256	0.00223	CcSEcCtD
Buprenorphine—Malnutrition—Carmustine—brain cancer	0.000256	0.00223	CcSEcCtD
Buprenorphine—Chills—Temozolomide—brain cancer	0.000255	0.00222	CcSEcCtD
Buprenorphine—Nervous system disorder—Hydroxyurea—brain cancer	0.000254	0.00221	CcSEcCtD
Buprenorphine—Infestation NOS—Etoposide—brain cancer	0.000253	0.00221	CcSEcCtD
Buprenorphine—Infestation—Etoposide—brain cancer	0.000253	0.00221	CcSEcCtD
Buprenorphine—Skin disorder—Hydroxyurea—brain cancer	0.000251	0.00219	CcSEcCtD
Buprenorphine—Mental disorder—Temozolomide—brain cancer	0.000249	0.00217	CcSEcCtD
Buprenorphine—ABCG2—midbrain—brain cancer	0.000248	0.00782	CbGeAlD
Buprenorphine—Back pain—Carmustine—brain cancer	0.000248	0.00216	CcSEcCtD
Buprenorphine—Malnutrition—Temozolomide—brain cancer	0.000248	0.00216	CcSEcCtD
Buprenorphine—Erythema—Temozolomide—brain cancer	0.000248	0.00216	CcSEcCtD
Buprenorphine—Anorexia—Hydroxyurea—brain cancer	0.000247	0.00215	CcSEcCtD
Buprenorphine—Hypersensitivity—Procarbazine—brain cancer	0.000246	0.00214	CcSEcCtD
Buprenorphine—Dysgeusia—Temozolomide—brain cancer	0.000242	0.00211	CcSEcCtD
Buprenorphine—ABCG2—spinal cord—brain cancer	0.000242	0.00763	CbGeAlD
Buprenorphine—Vision blurred—Carmustine—brain cancer	0.000241	0.0021	CcSEcCtD
Buprenorphine—Tremor—Carmustine—brain cancer	0.00024	0.00209	CcSEcCtD
Buprenorphine—Asthenia—Procarbazine—brain cancer	0.00024	0.00209	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Etoposide—brain cancer	0.00024	0.00209	CcSEcCtD
Buprenorphine—Back pain—Temozolomide—brain cancer	0.000239	0.00209	CcSEcCtD
Buprenorphine—CYP2D6—telencephalon—brain cancer	0.000237	0.00746	CbGeAlD
Buprenorphine—Pruritus—Procarbazine—brain cancer	0.000236	0.00206	CcSEcCtD
Buprenorphine—Agitation—Carmustine—brain cancer	0.000235	0.00205	CcSEcCtD
Buprenorphine—Vision blurred—Temozolomide—brain cancer	0.000233	0.00203	CcSEcCtD
Buprenorphine—Tremor—Temozolomide—brain cancer	0.000232	0.00202	CcSEcCtD
Buprenorphine—Dyspnoea—Hydroxyurea—brain cancer	0.000231	0.00201	CcSEcCtD
Buprenorphine—Somnolence—Hydroxyurea—brain cancer	0.00023	0.002	CcSEcCtD
Buprenorphine—Ill-defined disorder—Temozolomide—brain cancer	0.00023	0.002	CcSEcCtD
Buprenorphine—Diarrhoea—Procarbazine—brain cancer	0.000229	0.00199	CcSEcCtD
Buprenorphine—Dyspepsia—Hydroxyurea—brain cancer	0.000228	0.00198	CcSEcCtD
Buprenorphine—Agitation—Temozolomide—brain cancer	0.000227	0.00198	CcSEcCtD
Buprenorphine—Hypoaesthesia—Etoposide—brain cancer	0.000226	0.00197	CcSEcCtD
Buprenorphine—Angioedema—Temozolomide—brain cancer	0.000226	0.00197	CcSEcCtD
Buprenorphine—Decreased appetite—Hydroxyurea—brain cancer	0.000225	0.00196	CcSEcCtD
Buprenorphine—Urinary tract disorder—Etoposide—brain cancer	0.000225	0.00196	CcSEcCtD
Buprenorphine—CYP2C8—endocrine gland—brain cancer	0.000224	0.00706	CbGeAlD
Buprenorphine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000223	0.00195	CcSEcCtD
Buprenorphine—Malaise—Temozolomide—brain cancer	0.000223	0.00194	CcSEcCtD
Buprenorphine—Urethral disorder—Etoposide—brain cancer	0.000223	0.00194	CcSEcCtD
Buprenorphine—Fatigue—Hydroxyurea—brain cancer	0.000223	0.00194	CcSEcCtD
Buprenorphine—Vertigo—Temozolomide—brain cancer	0.000222	0.00194	CcSEcCtD
Buprenorphine—Convulsion—Carmustine—brain cancer	0.000222	0.00193	CcSEcCtD
Buprenorphine—Hypertension—Carmustine—brain cancer	0.000221	0.00193	CcSEcCtD
Buprenorphine—Constipation—Hydroxyurea—brain cancer	0.000221	0.00193	CcSEcCtD
Buprenorphine—Pain—Hydroxyurea—brain cancer	0.000221	0.00193	CcSEcCtD
Buprenorphine—Dizziness—Procarbazine—brain cancer	0.000221	0.00192	CcSEcCtD
Buprenorphine—Palpitations—Temozolomide—brain cancer	0.000219	0.00191	CcSEcCtD
Buprenorphine—Myalgia—Carmustine—brain cancer	0.000218	0.0019	CcSEcCtD
Buprenorphine—Chest pain—Carmustine—brain cancer	0.000218	0.0019	CcSEcCtD
Buprenorphine—Anxiety—Carmustine—brain cancer	0.000217	0.00189	CcSEcCtD
Buprenorphine—Cough—Temozolomide—brain cancer	0.000216	0.00188	CcSEcCtD
Buprenorphine—Convulsion—Temozolomide—brain cancer	0.000214	0.00187	CcSEcCtD
Buprenorphine—Hypertension—Temozolomide—brain cancer	0.000214	0.00186	CcSEcCtD
Buprenorphine—Feeling abnormal—Hydroxyurea—brain cancer	0.000213	0.00186	CcSEcCtD
Buprenorphine—Eye disorder—Etoposide—brain cancer	0.000213	0.00185	CcSEcCtD
Buprenorphine—Vomiting—Procarbazine—brain cancer	0.000212	0.00185	CcSEcCtD
Buprenorphine—Flushing—Etoposide—brain cancer	0.000211	0.00184	CcSEcCtD
Buprenorphine—Cardiac disorder—Etoposide—brain cancer	0.000211	0.00184	CcSEcCtD
Buprenorphine—Confusional state—Carmustine—brain cancer	0.000211	0.00184	CcSEcCtD
Buprenorphine—Myalgia—Temozolomide—brain cancer	0.000211	0.00184	CcSEcCtD
Buprenorphine—Arthralgia—Temozolomide—brain cancer	0.000211	0.00184	CcSEcCtD
Buprenorphine—Rash—Procarbazine—brain cancer	0.000211	0.00184	CcSEcCtD
Buprenorphine—Dermatitis—Procarbazine—brain cancer	0.00021	0.00183	CcSEcCtD
Buprenorphine—Anxiety—Temozolomide—brain cancer	0.00021	0.00183	CcSEcCtD
Buprenorphine—CYP1A2—endocrine gland—brain cancer	0.00021	0.00661	CbGeAlD
Buprenorphine—Headache—Procarbazine—brain cancer	0.000209	0.00182	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000209	0.00182	CcSEcCtD
Buprenorphine—Oedema—Carmustine—brain cancer	0.000209	0.00182	CcSEcCtD
Buprenorphine—Discomfort—Temozolomide—brain cancer	0.000208	0.00181	CcSEcCtD
Buprenorphine—Infection—Carmustine—brain cancer	0.000208	0.00181	CcSEcCtD
Buprenorphine—Angiopathy—Etoposide—brain cancer	0.000206	0.0018	CcSEcCtD
Buprenorphine—Dry mouth—Temozolomide—brain cancer	0.000206	0.0018	CcSEcCtD
Buprenorphine—Immune system disorder—Etoposide—brain cancer	0.000206	0.00179	CcSEcCtD
Buprenorphine—Mediastinal disorder—Etoposide—brain cancer	0.000205	0.00179	CcSEcCtD
Buprenorphine—Body temperature increased—Hydroxyurea—brain cancer	0.000204	0.00178	CcSEcCtD
Buprenorphine—Chills—Etoposide—brain cancer	0.000204	0.00178	CcSEcCtD
Buprenorphine—Tachycardia—Carmustine—brain cancer	0.000204	0.00178	CcSEcCtD
Buprenorphine—Confusional state—Temozolomide—brain cancer	0.000204	0.00177	CcSEcCtD
Buprenorphine—CYP3A5—endocrine gland—brain cancer	0.000202	0.00637	CbGeAlD
Buprenorphine—Oedema—Temozolomide—brain cancer	0.000202	0.00176	CcSEcCtD
Buprenorphine—Anaphylactic shock—Temozolomide—brain cancer	0.000202	0.00176	CcSEcCtD
Buprenorphine—Infection—Temozolomide—brain cancer	0.000201	0.00175	CcSEcCtD
Buprenorphine—Anorexia—Carmustine—brain cancer	0.000199	0.00174	CcSEcCtD
Buprenorphine—CYP2C9—endocrine gland—brain cancer	0.000199	0.00627	CbGeAlD
Buprenorphine—Nausea—Procarbazine—brain cancer	0.000198	0.00173	CcSEcCtD
Buprenorphine—Nervous system disorder—Temozolomide—brain cancer	0.000198	0.00173	CcSEcCtD
Buprenorphine—Skin disorder—Temozolomide—brain cancer	0.000196	0.00171	CcSEcCtD
Buprenorphine—Hypotension—Carmustine—brain cancer	0.000195	0.0017	CcSEcCtD
Buprenorphine—Hyperhidrosis—Temozolomide—brain cancer	0.000195	0.0017	CcSEcCtD
Buprenorphine—Dysgeusia—Etoposide—brain cancer	0.000194	0.00169	CcSEcCtD
Buprenorphine—Anorexia—Temozolomide—brain cancer	0.000193	0.00168	CcSEcCtD
Buprenorphine—ABCG2—cerebellum—brain cancer	0.000192	0.00605	CbGeAlD
Buprenorphine—Back pain—Etoposide—brain cancer	0.000192	0.00167	CcSEcCtD
Buprenorphine—Hypersensitivity—Hydroxyurea—brain cancer	0.000191	0.00166	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Carmustine—brain cancer	0.00019	0.00166	CcSEcCtD
Buprenorphine—Muscle spasms—Etoposide—brain cancer	0.00019	0.00166	CcSEcCtD
Buprenorphine—Insomnia—Carmustine—brain cancer	0.000189	0.00165	CcSEcCtD
Buprenorphine—Paraesthesia—Carmustine—brain cancer	0.000188	0.00164	CcSEcCtD
Buprenorphine—Dyspnoea—Carmustine—brain cancer	0.000186	0.00162	CcSEcCtD
Buprenorphine—Somnolence—Carmustine—brain cancer	0.000186	0.00162	CcSEcCtD
Buprenorphine—Asthenia—Hydroxyurea—brain cancer	0.000186	0.00162	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000184	0.0016	CcSEcCtD
Buprenorphine—Ill-defined disorder—Etoposide—brain cancer	0.000184	0.0016	CcSEcCtD
Buprenorphine—Insomnia—Temozolomide—brain cancer	0.000183	0.00159	CcSEcCtD
Buprenorphine—Decreased appetite—Carmustine—brain cancer	0.000182	0.00158	CcSEcCtD
Buprenorphine—Paraesthesia—Temozolomide—brain cancer	0.000181	0.00158	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Carmustine—brain cancer	0.00018	0.00157	CcSEcCtD
Buprenorphine—Dyspnoea—Temozolomide—brain cancer	0.00018	0.00157	CcSEcCtD
Buprenorphine—Somnolence—Temozolomide—brain cancer	0.00018	0.00156	CcSEcCtD
Buprenorphine—Pain—Carmustine—brain cancer	0.000179	0.00156	CcSEcCtD
Buprenorphine—Constipation—Carmustine—brain cancer	0.000179	0.00156	CcSEcCtD
Buprenorphine—Malaise—Etoposide—brain cancer	0.000179	0.00156	CcSEcCtD
Buprenorphine—Vertigo—Etoposide—brain cancer	0.000178	0.00155	CcSEcCtD
Buprenorphine—Dyspepsia—Temozolomide—brain cancer	0.000178	0.00155	CcSEcCtD
Buprenorphine—Diarrhoea—Hydroxyurea—brain cancer	0.000177	0.00154	CcSEcCtD
Buprenorphine—Decreased appetite—Temozolomide—brain cancer	0.000176	0.00153	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Temozolomide—brain cancer	0.000174	0.00152	CcSEcCtD
Buprenorphine—Fatigue—Temozolomide—brain cancer	0.000174	0.00152	CcSEcCtD
Buprenorphine—Loss of consciousness—Etoposide—brain cancer	0.000174	0.00152	CcSEcCtD
Buprenorphine—Cough—Etoposide—brain cancer	0.000173	0.00151	CcSEcCtD
Buprenorphine—Pain—Temozolomide—brain cancer	0.000173	0.00151	CcSEcCtD
Buprenorphine—Constipation—Temozolomide—brain cancer	0.000173	0.00151	CcSEcCtD
Buprenorphine—Feeling abnormal—Carmustine—brain cancer	0.000172	0.0015	CcSEcCtD
Buprenorphine—Convulsion—Etoposide—brain cancer	0.000172	0.0015	CcSEcCtD
Buprenorphine—Hypertension—Etoposide—brain cancer	0.000171	0.00149	CcSEcCtD
Buprenorphine—Dizziness—Hydroxyurea—brain cancer	0.000171	0.00149	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Carmustine—brain cancer	0.000171	0.00149	CcSEcCtD
Buprenorphine—ABCB1—telencephalon—brain cancer	0.00017	0.00537	CbGeAlD
Buprenorphine—Chest pain—Etoposide—brain cancer	0.000169	0.00147	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000167	0.00146	CcSEcCtD
Buprenorphine—Discomfort—Etoposide—brain cancer	0.000167	0.00145	CcSEcCtD
Buprenorphine—Feeling abnormal—Temozolomide—brain cancer	0.000166	0.00145	CcSEcCtD
Buprenorphine—Abdominal pain—Carmustine—brain cancer	0.000165	0.00144	CcSEcCtD
Buprenorphine—Body temperature increased—Carmustine—brain cancer	0.000165	0.00144	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Temozolomide—brain cancer	0.000165	0.00144	CcSEcCtD
Buprenorphine—Vomiting—Hydroxyurea—brain cancer	0.000164	0.00143	CcSEcCtD
Buprenorphine—Rash—Hydroxyurea—brain cancer	0.000163	0.00142	CcSEcCtD
Buprenorphine—Confusional state—Etoposide—brain cancer	0.000163	0.00142	CcSEcCtD
Buprenorphine—Dermatitis—Hydroxyurea—brain cancer	0.000163	0.00142	CcSEcCtD
Buprenorphine—Headache—Hydroxyurea—brain cancer	0.000162	0.00141	CcSEcCtD
Buprenorphine—Anaphylactic shock—Etoposide—brain cancer	0.000162	0.00141	CcSEcCtD
Buprenorphine—Infection—Etoposide—brain cancer	0.000161	0.0014	CcSEcCtD
Buprenorphine—Urticaria—Temozolomide—brain cancer	0.00016	0.0014	CcSEcCtD
Buprenorphine—CYP2C8—brain—brain cancer	0.00016	0.00505	CbGeAlD
Buprenorphine—Body temperature increased—Temozolomide—brain cancer	0.00016	0.00139	CcSEcCtD
Buprenorphine—Abdominal pain—Temozolomide—brain cancer	0.00016	0.00139	CcSEcCtD
Buprenorphine—Tachycardia—Etoposide—brain cancer	0.000158	0.00137	CcSEcCtD
Buprenorphine—Skin disorder—Etoposide—brain cancer	0.000157	0.00137	CcSEcCtD
Buprenorphine—Hyperhidrosis—Etoposide—brain cancer	0.000156	0.00136	CcSEcCtD
Buprenorphine—ABCG2—brain—brain cancer	0.000156	0.00491	CbGeAlD
Buprenorphine—Anorexia—Etoposide—brain cancer	0.000154	0.00134	CcSEcCtD
Buprenorphine—Hypersensitivity—Carmustine—brain cancer	0.000154	0.00134	CcSEcCtD
Buprenorphine—Nausea—Hydroxyurea—brain cancer	0.000154	0.00134	CcSEcCtD
Buprenorphine—CYP3A4—endocrine gland—brain cancer	0.000152	0.00478	CbGeAlD
Buprenorphine—Hypotension—Etoposide—brain cancer	0.000151	0.00132	CcSEcCtD
Buprenorphine—Asthenia—Carmustine—brain cancer	0.00015	0.00131	CcSEcCtD
Buprenorphine—CYP2D6—endocrine gland—brain cancer	0.000149	0.00471	CbGeAlD
Buprenorphine—Hypersensitivity—Temozolomide—brain cancer	0.000149	0.0013	CcSEcCtD
Buprenorphine—CYP2D6—head—brain cancer	0.000147	0.00465	CbGeAlD
Buprenorphine—Paraesthesia—Etoposide—brain cancer	0.000145	0.00126	CcSEcCtD
Buprenorphine—Asthenia—Temozolomide—brain cancer	0.000145	0.00126	CcSEcCtD
Buprenorphine—Dyspnoea—Etoposide—brain cancer	0.000144	0.00126	CcSEcCtD
Buprenorphine—Somnolence—Etoposide—brain cancer	0.000144	0.00125	CcSEcCtD
Buprenorphine—Diarrhoea—Carmustine—brain cancer	0.000143	0.00125	CcSEcCtD
Buprenorphine—Pruritus—Temozolomide—brain cancer	0.000143	0.00125	CcSEcCtD
Buprenorphine—ABCB1—gonad—brain cancer	0.000142	0.00448	CbGeAlD
Buprenorphine—Decreased appetite—Etoposide—brain cancer	0.000141	0.00122	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Etoposide—brain cancer	0.00014	0.00122	CcSEcCtD
Buprenorphine—Fatigue—Etoposide—brain cancer	0.000139	0.00121	CcSEcCtD
Buprenorphine—ABCB1—pituitary gland—brain cancer	0.000139	0.00437	CbGeAlD
Buprenorphine—Dizziness—Carmustine—brain cancer	0.000138	0.0012	CcSEcCtD
Buprenorphine—Pain—Etoposide—brain cancer	0.000138	0.0012	CcSEcCtD
Buprenorphine—Constipation—Etoposide—brain cancer	0.000138	0.0012	CcSEcCtD
Buprenorphine—Diarrhoea—Temozolomide—brain cancer	0.000138	0.0012	CcSEcCtD
Buprenorphine—CYP3A4—central nervous system—brain cancer	0.000137	0.00431	CbGeAlD
Buprenorphine—CYP2D6—central nervous system—brain cancer	0.000135	0.00424	CbGeAlD
Buprenorphine—ABCB1—medulla oblongata—brain cancer	0.000134	0.00422	CbGeAlD
Buprenorphine—Dizziness—Temozolomide—brain cancer	0.000134	0.00116	CcSEcCtD
Buprenorphine—Feeling abnormal—Etoposide—brain cancer	0.000133	0.00116	CcSEcCtD
Buprenorphine—Vomiting—Carmustine—brain cancer	0.000133	0.00116	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Etoposide—brain cancer	0.000132	0.00115	CcSEcCtD
Buprenorphine—Rash—Carmustine—brain cancer	0.000132	0.00115	CcSEcCtD
Buprenorphine—Dermatitis—Carmustine—brain cancer	0.000132	0.00115	CcSEcCtD
Buprenorphine—CYP2D6—cerebellum—brain cancer	0.000132	0.00415	CbGeAlD
Buprenorphine—Headache—Carmustine—brain cancer	0.000131	0.00114	CcSEcCtD
Buprenorphine—Vomiting—Temozolomide—brain cancer	0.000128	0.00112	CcSEcCtD
Buprenorphine—Urticaria—Etoposide—brain cancer	0.000128	0.00112	CcSEcCtD
Buprenorphine—Body temperature increased—Etoposide—brain cancer	0.000128	0.00111	CcSEcCtD
Buprenorphine—Abdominal pain—Etoposide—brain cancer	0.000128	0.00111	CcSEcCtD
Buprenorphine—Rash—Temozolomide—brain cancer	0.000127	0.00111	CcSEcCtD
Buprenorphine—Dermatitis—Temozolomide—brain cancer	0.000127	0.00111	CcSEcCtD
Buprenorphine—Headache—Temozolomide—brain cancer	0.000127	0.0011	CcSEcCtD
Buprenorphine—Nausea—Carmustine—brain cancer	0.000124	0.00108	CcSEcCtD
Buprenorphine—ABCB1—midbrain—brain cancer	0.000122	0.00385	CbGeAlD
Buprenorphine—Nausea—Temozolomide—brain cancer	0.00012	0.00105	CcSEcCtD
Buprenorphine—ABCB1—spinal cord—brain cancer	0.000119	0.00376	CbGeAlD
Buprenorphine—Hypersensitivity—Etoposide—brain cancer	0.000119	0.00104	CcSEcCtD
Buprenorphine—Asthenia—Etoposide—brain cancer	0.000116	0.00101	CcSEcCtD
Buprenorphine—Pruritus—Etoposide—brain cancer	0.000114	0.000996	CcSEcCtD
Buprenorphine—Diarrhoea—Etoposide—brain cancer	0.000111	0.000964	CcSEcCtD
Buprenorphine—ABCB1—endocrine gland—brain cancer	0.000107	0.00339	CbGeAlD
Buprenorphine—Dizziness—Etoposide—brain cancer	0.000107	0.000931	CcSEcCtD
Buprenorphine—CYP2D6—brain—brain cancer	0.000107	0.00337	CbGeAlD
Buprenorphine—ABCB1—head—brain cancer	0.000106	0.00334	CbGeAlD
Buprenorphine—Vomiting—Etoposide—brain cancer	0.000103	0.000895	CcSEcCtD
Buprenorphine—Rash—Etoposide—brain cancer	0.000102	0.000888	CcSEcCtD
Buprenorphine—Dermatitis—Etoposide—brain cancer	0.000102	0.000887	CcSEcCtD
Buprenorphine—Headache—Etoposide—brain cancer	0.000101	0.000882	CcSEcCtD
Buprenorphine—ABCB1—central nervous system—brain cancer	9.68e-05	0.00305	CbGeAlD
Buprenorphine—Nausea—Etoposide—brain cancer	9.6e-05	0.000837	CcSEcCtD
Buprenorphine—ABCB1—cerebellum—brain cancer	9.46e-05	0.00298	CbGeAlD
Buprenorphine—ABCB1—brain—brain cancer	7.69e-05	0.00242	CbGeAlD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	4.28e-05	0.000729	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—TRPC6—brain cancer	4.28e-05	0.000729	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	4.26e-05	0.000725	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—NOTCH2—brain cancer	4.22e-05	0.00072	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTCH2—brain cancer	4.05e-05	0.00069	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—SHH—brain cancer	4.03e-05	0.000686	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—VAV1—brain cancer	4.03e-05	0.000686	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—BSG—brain cancer	4.01e-05	0.000684	CbGpPWpGaD
Buprenorphine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	3.99e-05	0.000679	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.94e-05	0.000671	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HES5—brain cancer	3.92e-05	0.000668	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—TRPC6—brain cancer	3.88e-05	0.000662	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PTCH1—brain cancer	3.82e-05	0.000651	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—SMO—brain cancer	3.82e-05	0.000651	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STRADA—brain cancer	3.81e-05	0.000649	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—TRPC6—brain cancer	3.77e-05	0.000642	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—TRPC6—brain cancer	3.75e-05	0.000639	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CYP2C9—brain cancer	3.73e-05	0.000636	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	3.64e-05	0.00062	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ABR—brain cancer	3.62e-05	0.000617	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—SHH—brain cancer	3.53e-05	0.000602	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GLI2—brain cancer	3.5e-05	0.000596	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	3.49e-05	0.000596	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—IL2—brain cancer	3.48e-05	0.000593	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—HES1—brain cancer	3.46e-05	0.00059	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—IDH1—brain cancer	3.45e-05	0.000588	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	3.43e-05	0.000584	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTCH2—brain cancer	3.42e-05	0.000583	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	3.41e-05	0.000582	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—TRPC6—brain cancer	3.4e-05	0.00058	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	3.38e-05	0.000577	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—IL2—brain cancer	3.35e-05	0.000571	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PTCH1—brain cancer	3.35e-05	0.00057	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—SMO—brain cancer	3.35e-05	0.00057	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	3.35e-05	0.00057	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HES5—brain cancer	3.31e-05	0.000565	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PDGFRA—brain cancer	3.3e-05	0.000562	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GLI1—brain cancer	3.29e-05	0.000561	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	3.27e-05	0.000558	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	3.27e-05	0.000558	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—brain cancer	3.22e-05	0.00055	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STRADA—brain cancer	3.22e-05	0.000548	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—VAV1—brain cancer	3.2e-05	0.000546	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—SPP1—brain cancer	3.2e-05	0.000545	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ABR—brain cancer	3.18e-05	0.000541	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—BSG—brain cancer	3.17e-05	0.00054	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—TRPC6—brain cancer	3.17e-05	0.00054	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CYP2C9—brain cancer	3.16e-05	0.000539	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	3.15e-05	0.000536	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CYP2C9—brain cancer	3.14e-05	0.000535	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SUFU—brain cancer	3.12e-05	0.000532	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GLI2—brain cancer	3.07e-05	0.000523	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.07e-05	0.000523	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—IL2—brain cancer	3.05e-05	0.000519	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GFAP—brain cancer	3.01e-05	0.000513	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	3e-05	0.000511	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—SHH—brain cancer	2.98e-05	0.000509	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—VEGFA—brain cancer	2.96e-05	0.000504	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—VAV1—brain cancer	2.91e-05	0.000496	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IRS2—brain cancer	2.89e-05	0.000493	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GLI1—brain cancer	2.88e-05	0.000492	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.88e-05	0.00049	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—TRPC6—brain cancer	2.88e-05	0.00049	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CYP2C9—brain cancer	2.88e-05	0.00049	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HEY1—brain cancer	2.85e-05	0.000486	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PTCH1—brain cancer	2.83e-05	0.000482	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—SMO—brain cancer	2.83e-05	0.000482	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—VAV1—brain cancer	2.81e-05	0.000479	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—DLL1—brain cancer	2.8e-05	0.000477	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SUFU—brain cancer	2.73e-05	0.000466	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ENO2—brain cancer	2.73e-05	0.000465	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—IDH1—brain cancer	2.73e-05	0.000465	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—BSG—brain cancer	2.69e-05	0.000459	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ABR—brain cancer	2.69e-05	0.000458	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—BSG—brain cancer	2.67e-05	0.000455	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GFAP—brain cancer	2.64e-05	0.00045	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.62e-05	0.000447	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GLI2—brain cancer	2.59e-05	0.000442	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	2.59e-05	0.000442	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—APC—brain cancer	2.56e-05	0.000436	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PIK3CG—brain cancer	2.56e-05	0.000436	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—VAV1—brain cancer	2.55e-05	0.000435	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HEY1—brain cancer	2.5e-05	0.000426	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—DLL1—brain cancer	2.45e-05	0.000418	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—BSG—brain cancer	2.44e-05	0.000417	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	2.44e-05	0.000416	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GLI1—brain cancer	2.44e-05	0.000416	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SHH—brain cancer	2.38e-05	0.000405	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—VAV1—brain cancer	2.37e-05	0.000405	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—EGFR—brain cancer	2.33e-05	0.000397	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—IDH1—brain cancer	2.31e-05	0.000394	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SUFU—brain cancer	2.31e-05	0.000394	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—IDH1—brain cancer	2.29e-05	0.000391	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TRPC6—brain cancer	2.29e-05	0.000391	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CYP2C9—brain cancer	2.27e-05	0.000386	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTCH1—brain cancer	2.25e-05	0.000384	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SMO—brain cancer	2.25e-05	0.000384	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.24e-05	0.000382	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GFAP—brain cancer	2.23e-05	0.00038	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.22e-05	0.000378	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—VAV1—brain cancer	2.16e-05	0.000367	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ENO2—brain cancer	2.16e-05	0.000367	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HEY1—brain cancer	2.11e-05	0.00036	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—IDH1—brain cancer	2.1e-05	0.000358	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SHH—brain cancer	2.09e-05	0.000355	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—DLL1—brain cancer	2.07e-05	0.000353	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	2.04e-05	0.000347	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—PIK3CG—brain cancer	2.03e-05	0.000347	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TRPC6—brain cancer	2.01e-05	0.000343	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—RELA—brain cancer	2e-05	0.00034	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—ERBB2—brain cancer	1.98e-05	0.000338	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTCH1—brain cancer	1.98e-05	0.000337	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SMO—brain cancer	1.98e-05	0.000337	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP2C9—brain cancer	1.96e-05	0.000335	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—BSG—brain cancer	1.93e-05	0.000329	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	1.89e-05	0.000323	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PIK3CG—brain cancer	1.85e-05	0.000315	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ENO2—brain cancer	1.83e-05	0.000312	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ENO2—brain cancer	1.81e-05	0.000309	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NOTCH2—brain cancer	1.8e-05	0.000307	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IL2—brain cancer	1.8e-05	0.000307	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PIK3CG—brain cancer	1.78e-05	0.000304	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SHH—brain cancer	1.76e-05	0.0003	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCND1—brain cancer	1.75e-05	0.000299	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP2C9—brain cancer	1.75e-05	0.000299	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CTNNB1—brain cancer	1.74e-05	0.000296	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VAV1—brain cancer	1.72e-05	0.000293	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP2C9—brain cancer	1.71e-05	0.000292	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TRPC6—brain cancer	1.7e-05	0.00029	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	1.67e-05	0.000285	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SMO—brain cancer	1.67e-05	0.000285	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTCH1—brain cancer	1.67e-05	0.000285	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—BSG—brain cancer	1.67e-05	0.000285	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ENO2—brain cancer	1.66e-05	0.000283	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—IDH1—brain cancer	1.66e-05	0.000283	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	1.66e-05	0.000282	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CG—brain cancer	1.62e-05	0.000276	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP2C9—brain cancer	1.61e-05	0.000275	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NOTCH2—brain cancer	1.58e-05	0.000269	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—VEGFA—brain cancer	1.53e-05	0.000261	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—STAT3—brain cancer	1.51e-05	0.000258	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CG—brain cancer	1.51e-05	0.000257	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VAV1—brain cancer	1.51e-05	0.000257	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—BSG—brain cancer	1.49e-05	0.000254	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HES1—brain cancer	1.48e-05	0.000252	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	1.46e-05	0.000249	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—BSG—brain cancer	1.45e-05	0.000248	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—IDH1—brain cancer	1.44e-05	0.000245	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—IL2—brain cancer	1.43e-05	0.000244	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PDGFRA—brain cancer	1.41e-05	0.00024	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MYC—brain cancer	1.41e-05	0.00024	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—EGFR—brain cancer	1.38e-05	0.000234	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—BSG—brain cancer	1.37e-05	0.000234	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CG—brain cancer	1.37e-05	0.000233	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SPP1—brain cancer	1.37e-05	0.000233	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP2C9—brain cancer	1.37e-05	0.000233	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—BSG—brain cancer	1.36e-05	0.000232	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	1.34e-05	0.000229	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NOTCH2—brain cancer	1.34e-05	0.000228	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	1.31e-05	0.000224	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ENO2—brain cancer	1.31e-05	0.000223	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL2—brain cancer	1.3e-05	0.000222	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HES1—brain cancer	1.3e-05	0.000221	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—IDH1—brain cancer	1.28e-05	0.000218	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VAV1—brain cancer	1.27e-05	0.000217	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—IL2—brain cancer	1.26e-05	0.000214	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—IDH1—brain cancer	1.25e-05	0.000213	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CG—brain cancer	1.25e-05	0.000213	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IRS2—brain cancer	1.24e-05	0.000211	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PDGFRA—brain cancer	1.23e-05	0.00021	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SPP1—brain cancer	1.2e-05	0.000204	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—IDH1—brain cancer	1.18e-05	0.000201	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.17e-05	0.000199	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—IDH1—brain cancer	1.17e-05	0.000199	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—BSG—brain cancer	1.16e-05	0.000198	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—brain cancer	1.16e-05	0.000197	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL2—brain cancer	1.14e-05	0.000194	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ENO2—brain cancer	1.14e-05	0.000193	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	1.1e-05	0.000188	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HES1—brain cancer	1.1e-05	0.000187	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—APC—brain cancer	1.09e-05	0.000186	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CG—brain cancer	1.09e-05	0.000186	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IRS2—brain cancer	1.08e-05	0.000185	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—IL2—brain cancer	1.06e-05	0.000181	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2C9—brain cancer	1.05e-05	0.00018	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.04e-05	0.000178	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PDGFRA—brain cancer	1.04e-05	0.000178	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ENO2—brain cancer	1.01e-05	0.000173	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SPP1—brain cancer	1.01e-05	0.000173	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—IDH1—brain cancer	9.99e-06	0.00017	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—EGFR—brain cancer	9.94e-06	0.000169	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CG—brain cancer	9.89e-06	0.000169	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ENO2—brain cancer	9.89e-06	0.000169	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL2—brain cancer	9.63e-06	0.000164	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—APC—brain cancer	9.57e-06	0.000163	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CG—brain cancer	9.57e-06	0.000163	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	9.52e-06	0.000162	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ENO2—brain cancer	9.32e-06	0.000159	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ENO2—brain cancer	9.24e-06	0.000157	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IRS2—brain cancer	9.16e-06	0.000156	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—BSG—brain cancer	8.96e-06	0.000153	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EGFR—brain cancer	8.72e-06	0.000149	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RELA—brain cancer	8.53e-06	0.000145	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ERBB2—brain cancer	8.47e-06	0.000144	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CG—brain cancer	8.39e-06	0.000143	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CG—brain cancer	8.32e-06	0.000142	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	8.13e-06	0.000139	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—APC—brain cancer	8.09e-06	0.000138	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CG—brain cancer	8.09e-06	0.000138	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ENO2—brain cancer	7.89e-06	0.000135	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—IDH1—brain cancer	7.71e-06	0.000131	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL2—brain cancer	7.68e-06	0.000131	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CG—brain cancer	7.62e-06	0.00013	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—brain cancer	7.49e-06	0.000128	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RELA—brain cancer	7.48e-06	0.000127	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB2—brain cancer	7.43e-06	0.000127	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CTNNB1—brain cancer	7.41e-06	0.000126	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—brain cancer	7.37e-06	0.000126	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL2—brain cancer	6.73e-06	0.000115	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—brain cancer	6.56e-06	0.000112	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—brain cancer	6.53e-06	0.000111	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CTNNB1—brain cancer	6.5e-06	0.000111	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—brain cancer	6.46e-06	0.00011	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RELA—brain cancer	6.32e-06	0.000108	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—brain cancer	6.28e-06	0.000107	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO2—brain cancer	6.09e-06	0.000104	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CG—brain cancer	6.01e-06	0.000102	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—brain cancer	6e-06	0.000102	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—brain cancer	5.87e-06	0.0001	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—brain cancer	5.72e-06	9.75e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—brain cancer	5.69e-06	9.7e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—brain cancer	5.67e-06	9.66e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—brain cancer	5.55e-06	9.45e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CTNNB1—brain cancer	5.49e-06	9.36e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—brain cancer	5.26e-06	8.97e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CG—brain cancer	5.21e-06	8.87e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—brain cancer	5.15e-06	8.78e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—brain cancer	4.93e-06	8.4e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—brain cancer	4.84e-06	8.24e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—brain cancer	4.79e-06	8.16e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CG—brain cancer	4.65e-06	7.92e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CG—brain cancer	4.54e-06	7.73e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—brain cancer	4.45e-06	7.58e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—brain cancer	4.35e-06	7.42e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—brain cancer	4.32e-06	7.37e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CG—brain cancer	4.28e-06	7.29e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CG—brain cancer	4.24e-06	7.22e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—brain cancer	3.65e-06	6.23e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CG—brain cancer	3.62e-06	6.17e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CG—brain cancer	2.8e-06	4.76e-05	CbGpPWpGaD
